Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Edward Boghosian who wrote (1678)	1/6/2000 7:39:00 PM
From: arnie h	Read Replies (1) \| Respond to of 2173

Ed; You took the words right out of my mouth. Presumably, something positive since the price jumped today. It would be even better if she said something negative and the price jumped anyway. Arnie

To: Edward Boghosian who wrote (1678)	1/6/2000 8:43:00 PM
From: Lynn Peters	Read Replies (1) \| Respond to of 2173

Since you asked I will give you a summary. "Persistence pays off...." Amylin has completed extensive clinical trials including 3 Phase III trials for Type I diabetes and 3 Phase III trials for Type II diabetes. Symlin has shown encouraging results for the regulation of blood glucose which would reduce very serious secondary complications such as blindness and the damaging effect of diabetes on the central nervous system and kidneys. An added benefit of using Symlin is Type II insulin users actually lost weight while using Symlin instead of gaining weight. This in turn encourages patients to use their drugs. It was the analysts opinion that all things considered AMLN should get FDA approval. AMLN is now putting together documents for filing mid-year 2000 and should get approval by mid-year 2001. She went on to say that there is a large market for diabetes drugs and the FDA is favorably looking at anything that could help with better control of blood glucose. Her stock price projection for 2001 is a conservative $12 per share. She says that the company is now in discussions with potential marketing partners for Symlin which in her opinion would cause her to reevaluate and increase her conservative price upward. She expects AMLN would collaborate with a partner the first half of this year with a profit sharing 50% 50% arrangement instead of the less profitable royalty arrangement which was usual in the past. Some of the potential marketing partners she mentioned were Eli Lilly, Bristol-Myers Squibb, Upjohn and Smithkline Beecham.. Lynn Peters